Literature DB >> 27867636

Oligometastases to the liver: predicting outcomes based upon radiation sensitivity.

Haoming Qiu1, Alan W Katz1, Michael T Milano1.   

Abstract

Year:  2016        PMID： 27867636      PMCID： PMC5107502          DOI： 10.21037/jtd.2016.10.88

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial.

Authors:  Marta Scorsetti; Stefano Arcangeli; Angelo Tozzi; Tiziana Comito; Filippo Alongi; Pierina Navarria; Pietro Mancosu; Giacomo Reggiori; Antonella Fogliata; Guido Torzilli; Stefano Tomatis; Luca Cozzi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-02-20       Impact factor: 7.038

2.  Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer.

Authors:  Atsuya Takeda; Etsuo Kunieda; Toshio Ohashi; Yousuke Aoki; Naoyoshi Koike; Toshiaki Takeda
Journal:  Radiother Oncol       Date:  2011-11       Impact factor: 6.280

3.  Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study.

Authors:  Andrea Riccardo Filippi; Serena Badellino; Manuela Ceccarelli; Alessia Guarneri; Pierfrancesco Franco; Chiara Monagheddu; Rosella Spadi; Riccardo Ragona; Patrizia Racca; Umberto Ricardi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-12-24       Impact factor: 7.038

4.  A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases.

Authors:  Tracey E Schefter; Brian D Kavanagh; Robert D Timmerman; Higinia R Cardenes; Anna Baron; Laurie E Gaspar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-01       Impact factor: 7.038

5.  Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.

Authors:  Michael T Milano; Alan W Katz; Hong Zhang; Paul Okunieff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-13       Impact factor: 7.038

6.  Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence.

Authors:  K S Hughes; R Simon; S Songhorabodi; M A Adson; D M Ilstrup; J G Fortner; B J Maclean; J H Foster; J M Daly; D Fitzherbert
Journal:  Surgery       Date:  1986-08       Impact factor: 3.982

7.  Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management.

Authors:  Rohann J M Correa; Joseph K Salama; Michael T Milano; David A Palma
Journal:  Cancer J       Date:  2016 Jul-Aug       Impact factor: 3.360

8.  Phase I study of individualized stereotactic body radiotherapy of liver metastases.

Authors:  Mark T Lee; John J Kim; Robert Dinniwell; James Brierley; Gina Lockwood; Rebecca Wong; Bernard Cummings; Jolie Ringash; Regina V Tse; Jennifer J Knox; Laura A Dawson
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

9.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases.

Authors:  Kyle E Rusthoven; Brian D Kavanagh; Higinia Cardenes; Volker W Stieber; Stuart H Burri; Steven J Feigenberg; Mark A Chidel; Thomas J Pugh; Wilbur Franklin; Madeleine Kane; Laurie E Gaspar; Tracey E Schefter
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

10.  Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy.

Authors:  Kamran A Ahmed; Jimmy J Caudell; Ghassan El-Haddad; Anders E Berglund; Eric A Welsh; Binglin Yue; Sarah E Hoffe; Arash O Naghavi; Yazan A Abuodeh; Jessica M Frakes; Steven A Eschrich; Javier F Torres-Roca
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-04-08       Impact factor: 7.038
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.